Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...